AbbVie announced favorable Phase 1 clinical results for its metabolic pipeline candidate, ABBV-295. The data indicates a 11- to 12-day half-life and dose-proportional plasma exposure, providing a strong foundation for less frequent dosing schedules.
AbbVie presented favorable Phase 1 data for ABBV-295, showing a long half-life and dose-proportional exposure, supporting less frequent dosing and advancing its metabolic pipeline.